Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/17/?d=1Neue Studien: Europe PMCdeComposite Outcome Measures for Psoriatic Arthritis: Project Updates 2024.https://www.psoriasis-news.de/articles.html/1_articles/composite-outcome-measures-for-psoriatic-arthritis-project-updates-2024-r215/Weiterlesen

]]>215Sun, 24 Aug 2025 17:56:41 +0000Causal Effect of Plasma Fatty Acid Profiles on Psoriasis Risk: Genetic Evidence from a Mendelian Randomization Study.https://www.psoriasis-news.de/articles.html/1_articles/causal-effect-of-plasma-fatty-acid-profiles-on-psoriasis-risk-genetic-evidence-from-a-mendelian-randomization-study-r214/Weiterlesen

]]>214Sun, 24 Aug 2025 17:56:41 +0000Characterising Alternative Diagnoses to Psoriatic Arthritis in a Rheumatology-Dermatology Combined Clinic.https://www.psoriasis-news.de/articles.html/1_articles/characterising-alternative-diagnoses-to-psoriatic-arthritis-in-a-rheumatology-dermatology-combined-clinic-r213/Weiterlesen

]]>213Sun, 24 Aug 2025 17:56:41 +0000Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/clinical-efficacy-of-308%C2%A0nm-excimer-laser-irradiation-combined-with-01-tacrolimus-ointment-in-the-treatment-of-plaque-type-psoriasis-r212/Weiterlesen

]]>212Sun, 24 Aug 2025 17:56:41 +0000Beyond Skin Clearance: Personalized Strategies for DLQI Improvement in Psoriasis -Insights From a Shanghai Prospective Cohort.https://www.psoriasis-news.de/articles.html/1_articles/beyond-skin-clearance-personalized-strategies-for-dlqi-improvement-in-psoriasis-insights-from-a-shanghai-prospective-cohort-r211/IntroductionPsoriasis is a chronic immune-mediated disease that significantly impacts patients clinically and psychologically. Physician-assessed severity measures, including Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician Global Assessment (PGA), often fail to capture patient-reported outcomes, particularly when clinical improvement and perceived quality-of-life gains are misaligned.

Purpose

To clarify the association between clinical improvements and Dermatology Life Quality Index (DLQI) outcomes, identify predictors of substantial DLQI improvement (≥90% reduction), and explore reasons for suboptimal DLQI responses in patients achieving skin clearance.

Methods

In this 12-week prospective study, 551 psoriasis patients were enrolled at Shanghai Skin Diseases Hospital. Data on demographics, clinical severity (PASI, BSA, and PGA), DLQI scores, and treatment modalities were collected. Logistic regression analyses were employed to assess the dose-response relationships between improvements in clinical parameters and DLQI reduction, and to identify factors of suboptimal DLQI improvement among patients achieving significant skin clearance.

Results

Median DLQI improved significantly (8.0 to 3.0) at week 12, with 24.1% of patients achieving ≥90% DLQI reduction. Strong dose-response associations existed between clinical severity improvements (PASI, BSA, PGA) and DLQI gains. PASI75 responders were significantly more likely to achieve substantial DLQI improvement (OR = 2.48, 95% CI: 1.51-4.07). However, only 33.3% of PASI75 achievers reached ≥90% DLQI improvement. Early clinical response (as early as week 4) strongly predicted superior DLQI outcomes. Female sex, older age, lower baseline DLQI scores, and shorter disease duration were associated with achieving high skin clearance but suboptimal DLQI improvement.

Conclusion

Early clinical response effectively predicts substantial DLQI improvement, whereas demographic and disease-related factors help identify patients at risk for suboptimal quality-of-life gains despite significant skin clearance. These insights support personalized therapeutic strategies aimed at improving patient satisfaction beyond skin clearance alone.

Weiterlesen

]]>211Sat, 23 Aug 2025 09:33:52 +0000GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.https://www.psoriasis-news.de/articles.html/1_articles/glp-1-receptor-agonists-emerging-therapeutic-potential-in-psoriasis-management-current-evidence-and-future-outlook-r210/Weiterlesen

]]>210Sat, 23 Aug 2025 09:18:30 +0000Friend or foe? Sebaceous cyst inflammation during ixekizumab therapy in psoriatic arthritis: case based review.https://www.psoriasis-news.de/articles.html/1_articles/friend-or-foe-sebaceous-cyst-inflammation-during-ixekizumab-therapy-in-psoriatic-arthritis-case-based-review-r209/Weiterlesen

]]>209Sat, 23 Aug 2025 09:18:30 +0000Association between metabolic score for visceral fat and psoriasis: findings from NHANES.https://www.psoriasis-news.de/articles.html/1_articles/association-between-metabolic-score-for-visceral-fat-and-psoriasis-findings-from-nhanes-r208/BackgroundPsoriasis is a persistent inflammatory skin condition. Several studies have revealed that obesity significantly contributes to both the initiation and advancement of psoriasis. The metabolic score for visceral fat (METS-VF) represents an innovative measure designed to forecast visceral obesity, integrating factors such as insulin resistance metabolic score, waist-to-hip ratio (WHR), age, and gender. The present study aimed to investigate the association between METS-VF and psoriasis prevalence, using information gathered from the National Health and Nutrition Examination Survey (NHANES).

Methods

This study utilized the data from a nationally representative cohort of 8023 adults from NHANES from 2003-2006 to 2009-2014, of which 234 declared a psoriasis history. Multivariate logistic regression analysis and restricted cubic spline (RCS) analyses were used to investigate the association between METS-VF and psoriasis, followed by subgroup analysis to identify populations that may exhibit higher sensitivity.

Results

After adjusting for confounding variables, the results of the multivariate logistic regression analysis showed a significant positive association between METS-VF and the risk of psoriasis. One-unit increasement in METS-VF corresponded to a 47% rise in psoriasis risk (odds ratio [OR] = 1.47, 95% confidence interval [CI] = 1.10-1.96). Finally, the results were uniform across all subgroups (P for interaction > 0.05). The results from the RCS analysis indicated a notable linear association.

Conclusion

This research indicated that elevated levels of METS-VF are linked to a higher occurrence of psoriasis, suggesting the potential of METS-VF as a predictive anthropometric index for assessing the risk of developing psoriasis.

Weiterlesen

]]>208Sat, 23 Aug 2025 09:18:30 +0000Effects of Acute Time-Restricted Eating on Inflammation in Individuals With Psoriasis: Protocol for a Case-Control, Prospective Study.https://www.psoriasis-news.de/articles.html/1_articles/effects-of-acute-time-restricted-eating-on-inflammation-in-individuals-with-psoriasis-protocol-for-a-case-control-prospective-study-r207/BackgroundPsoriasis is a chronic inflammatory disease associated with multiple comorbidities, including metabolic syndrome and cardiovascular disease. Although specific dietary interventions, such as intermittent fasting and caloric restriction, have been shown to ameliorate inflammation and promote weight loss, the effect of these interventions independent of weight loss remains unclear. Time-restricted eating (TRE), a type of intermittent fasting, limits the daily eating window to a fixed number of hours. Recent studies suggest TRE may improve immune function in individuals with metabolic syndrome and cardiovascular risk factors. A crucial advantage of TRE over other investigated dietary restriction strategies is its reported high adherence rate, making it a more feasible intervention for long-term use. Therefore, exploring the effects of TRE on metabolic and immunological parameters in psoriasis is warranted.

Objective

This study was designed to evaluate the effects of short-term, isocaloric TRE, independent of weight loss, on immune cell function and serum metabolite profiles of volunteers with mild-to-moderate psoriasis compared to healthy individuals.

Methods

This case-control, prospective study was performed on 10 healthy male participants and 10 age-, BMI-, and sex-matched individuals with mild-to-moderate psoriasis. All individuals with psoriasis had stable disease and were being treated with topical therapies without any exposure to immunomodulatory biologics. This study was conducted at the National Institutes of Health Clinical Center. Immune profiles, glucose handling, energy expenditure, and participants' weights were assessed at baseline and after 3 days of TRE following a daily 6-hour eating window and 18-hour fast.

Results

The trial commenced in June 2021 and was completed in February 2023. A total of 20 participants were enrolled-10 with mild-to-moderate psoriasis and 10 age-, BMI-, and sex-matched healthy individuals. As of the time of manuscript submission, data processing is ongoing. Multiomic datasets, including gene expression, surface and intracellular protein levels, and metabolite profiles, are being generated from peripheral blood mononuclear cells, CD4+-enriched T-cells, and serum samples. The integrated bioinformatics analyses will be reported once the data analysis is completed.

Conclusions

This clinical protocol was designed to characterize the effects of short term (3-day) TRE on psoriasis, independent of weight loss, by comparing immune cell regulatory responses between healthy individuals and those with psoriasis. More specifically, we aim to map the molecular pathways activated by TRE and assess how they affect immune cell composition, activation, and metabolism. Additionally, components of the metabolic response to isocaloric TRE are being explored. Insights into how dietary interventions impact metabolism and the immune system will enhance our understanding of the pathogenesis of psoriasis and may reveal new therapeutic avenues for managing this inflammatory condition.

Trial registration

ClinicalTrials.gov NCT04728165; https://clinicaltrials.gov/study/NCT04728165.

Weiterlesen

]]>207Sat, 23 Aug 2025 09:18:30 +0000JNK/c-Jun cascade activation enhances malignant proliferation of psoriatic keratinocytes by regulating ROS levels and mitochondrial membrane potential.https://www.psoriasis-news.de/articles.html/1_articles/jnkc-jun-cascade-activation-enhances-malignant-proliferation-of-psoriatic-keratinocytes-by-regulating-ros-levels-and-mitochondrial-membrane-potential-r206/Weiterlesen

]]>206Sat, 23 Aug 2025 09:18:30 +0000Impact of psoriasis on THA and TKA outcomes: A systematic review.https://www.psoriasis-news.de/articles.html/1_articles/impact-of-psoriasis-on-tha-and-tka-outcomes-a-systematic-review-r205/Weiterlesen

]]>205Sat, 23 Aug 2025 09:18:30 +0000Exosome mediated delivery of Epigallocatechin 3 gallate as a novel approach to alleviate psoriasis symptoms through cytokine and apoptotic pathway modulation.https://www.psoriasis-news.de/articles.html/1_articles/exosome-mediated-delivery-of-epigallocatechin-3-gallate-as-a-novel-approach-to-alleviate-psoriasis-symptoms-through-cytokine-and-apoptotic-pathway-modulation-r204/Weiterlesen

]]>204Sat, 23 Aug 2025 09:18:30 +0000Psychosocial Burden of Visible Psoriasis Vulgaris Lesions: A Case-Control Study on Social Appearance Anxiety and Psychological Well-Beinghttps://www.psoriasis-news.de/articles.html/1_articles/psychosocial-burden-of-visible-psoriasis-vulgaris-lesions-a-case-control-study-on-social-appearance-anxiety-and-psychological-well-being-r203/Background: Psoriasis vulgaris, particularly when manifesting in highly visible regions such as the face and hands, can profoundly impair self-perception and social functioning. Despite a growing interest in psychodermatology, the specific impact of visible psoriatic lesions on social appearance anxiety remains insufficiently explored.

Objective:

To assess the severity of social appearance anxiety in patients with visible psoriasis vulgaris lesions compared to healthy controls, and to examine its associations with general anxiety, depression, perceived disease severity, and dermatology-related quality of life.

Methods:

A cross-sectional case-control study was conducted involving 178 patients diagnosed with psoriasis vulgaris exhibiting visible skin lesions and 196 age- and sex-matched healthy controls. All participants completed the Social Appearance Anxiety Scale (SAAS) and the Hospital Anxiety and Depression Scale (HADS). Patients additionally completed the Dermatology Life Quality Index (DLQI) and a Visual Analog Scale (VAS) to evaluate subjective disease severity. Statistical analyses included group comparisons and Pearson correlations between psychological and clinical parameters.

Results:

SAAS scores were significantly elevated in the patient group (mean = 60.32 ± 8.10) compared to controls (mean = 22.15 ± 9.05; p < 0.001), indicating a large effect size. In psoriasis patients, social appearance anxiety showed a moderate positive correlation with perceived disease severity (r = 0.293, p < 0.01), while correlations with DLQI and depression scores were not statistically significant. General anxiety levels (HADS-A) demonstrated a moderate correlation with SAAS (r = 0.484, p < 0.01).

Conclusion:

Visible lesions in psoriasis vulgaris contribute substantially to social appearance anxiety, independent of general psychopathology. These findings underscore the psychological vulnerability of patients with visible psoriatic involvement and highlight the need for integrated psychosocial interventions as part of comprehensive dermatological care.

Weiterlesen

]]>203Sat, 23 Aug 2025 09:18:30 +0000Traditional Siddha Therapy Using Sivappu Kukkil Thailam (Topical) and Seendhil Chooranam (Oral) for Chronic Plaque Psoriasis: A Single-Patient Case Following the CAse REport (CARE) Guidelineshttps://www.psoriasis-news.de/articles.html/1_articles/traditional-siddha-therapy-using-sivappu-kukkil-thailam-topical-and-seendhil-chooranam-oral-for-chronic-plaque-psoriasis-a-single-patient-case-following-the-case-report-care-guidelines-r202/No abstract supplied.

Weiterlesen

]]>202Sat, 23 Aug 2025 09:18:30 +0000Risk of Serious Infection With Adalimumab in Hidradenitis Suppurativa Compared With Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/risk-of-serious-infection-with-adalimumab-in-hidradenitis-suppurativa-compared-with-psoriasis-r201/Weiterlesen

]]>201Sat, 23 Aug 2025 09:18:30 +0000Scalable Dynamic Scale Proposals for Psoriasis Lesions Detectionhttps://www.psoriasis-news.de/articles.html/1_articles/scalable-dynamic-scale-proposals-for-psoriasis-lesions-detection-r192/Psoriasis is a chronic skin condition characterized by the rapid growth of skin cells, leading to the formation of thick, scaly patches. Detecting these lesions accurately is crucial for early diagnosis and effective treatment. However, the variability in lesion size, shape, and appearance across different skin types presents significant challenges for automated detection systems. Traditional methods often struggle with these variations, leading to reduced accuracy and efficiency. In recent years, convolutional neural networks (CNNs) have emerged as a powerful tool for medical image analysis, particularly in the detection of skin conditions. This paper introduces a novel approach for psoriasis lesion detection using convolutional neural networks (CNNs). The challenge of accurately identifying lesions across various skin types and lesion sizes is addressed by leveraging a scale-aware strategy. In this method, a CNN first estimates the scale distribution of psoriasis lesions within an image by predicting a scale histogram. This histogram serves as a guide for image scaling operations, ensuring that lesions are brought to a uniform scale for subsequent detection. By applying zoom-in and zoom-out transformations based on the predicted scale histogram, the model reduces computational overhead while maintaining high detection accuracy. The proposed approach demonstrates improved efficiency and accuracy in identifying psoriasis lesions, as compared to traditional multi-scale testing techniques, with reduced computational demands. Extensive qualitative and quantitative evaluations on various skin datasets show that the scale-aware strategy significantly enhances lesion detection performance, making it a promising tool for automated psoriasis diagnosis.

Weiterlesen

]]>192Sat, 23 Aug 2025 07:41:28 +0000Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: a meta-analysis.https://www.psoriasis-news.de/articles.html/1_articles/prevalence-of-metabolic-syndrome-and-its-components-in-psoriatic-arthritis-compared-with-general-population-cutaneous-psoriasis-and-other-inflammatory-arthropathies-a-meta-analysis-r191/ObjectivesThrough this meta-analysis, we aim to provide an overview and statistical synthesis of the prevalence of MetS and its components in psoriatic arthritis (PsA) compared to the general populations, patients with cutaneous psoriasis (PsO), and patients with other inflammatory arthropathies.

Method

A search was conducted in Ovid Medline, Web of Science, and Scopus up to February 2024. Original articles investigating the prevalence of MetS in PsA in adults compared to one or more comparison populations were included. Bias risk was assessed by means of a funnel plot. The data was analyzed by means of a random effects model and presented in forest plots.

Results

Of 1526 articles in the original search, 20 relevant were identified. Meta-analyses showed an increased prevalence of MetS in PsA compared to the general population, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) (LogOR 0.93, 0.63, and 1.04, respectively). Meta-analysis showed no difference in the prevalence of MetS in PsA compared to PsO (LogOR 0.15, I2 0.63). Meta-analysis of the prevalence of the different components of MetS in PsA compared to RA showed an increased prevalence of central obesity, hypertriglyceridemia, impaired glucose tolerance, and diabetes mellitus.

Conclusions

PsA was associated with an increased risk of MetS compared to the risk in the general population, in RA and in AS, respectively. This emphasizes the importance of screening for and taking necessary measures to prevent MetS in patients with PsA. Key Points • Patients with PsA have an increased risk of MetS compared to the general population as well as patients with RA or AS. • According to this meta-analysis, the risk of MetS is the same in patients with PsA as in patients with PsO.

Weiterlesen

]]>191Sat, 23 Aug 2025 07:41:28 +0000Checkpoint agonists - immunoregulatory role and its implications in the treatment of psoriasis and psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/checkpoint-agonists-immunoregulatory-role-and-its-implications-in-the-treatment-of-psoriasis-and-psoriatic-arthritis-r190/Weiterlesen

]]>190Sat, 23 Aug 2025 07:41:28 +0000A Large‐Scale, Retrospective Analysis of Bath‐Psoralen Plus Ultraviolet A Therapy for Psoriasis: A Single‐Center Studyhttps://www.psoriasis-news.de/articles.html/1_articles/a-large%E2%80%90scale-retrospective-analysis-of-bath%E2%80%90psoralen-plus-ultraviolet-a-therapy-for-psoriasis-a-single%E2%80%90center-study-r189/No abstract supplied.

Weiterlesen

]]>189Sat, 23 Aug 2025 07:41:28 +0000Sustained Efficacy and Safety of Tildrakizumab in Psoriasis Vulgaris Despite Multiple Prolonged Treatment Interruptions: A Case Reporthttps://www.psoriasis-news.de/articles.html/1_articles/sustained-efficacy-and-safety-of-tildrakizumab-in-psoriasis-vulgaris-despite-multiple-prolonged-treatment-interruptions-a-case-report-r188/No abstract supplied.

Weiterlesen

]]>188Sat, 23 Aug 2025 07:41:28 +0000TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses.https://www.psoriasis-news.de/articles.html/1_articles/tyk2-rs34536443-p1104a-variant-suppresses-icam1-mediated-inflammation-insights-from-mendelian-randomization-and-functional-analyses-r187/BackgroundGenetic susceptibility to psoriasis involves multiple loci, including TYK2 (Tyrosine Kinase 2), which is associated with various autoimmune diseases. However, its specific role and mechanisms in psoriasis remain unclear. This study aimed to identify psoriasis-associated proteins using Summary-based Mendelian Randomization (SMR) and to explore their regulatory mechanisms.

Methods

SMR analysis integrating pQTL data was conducted to identify proteins linked to psoriasis, revealing ICAM1 (Intercellular Adhesion Molecule 1) as a potential pathogenic factor. A key SNP, rs34536443 (P1104A), located in TYK2, was found to regulate ICAM1. To assess its function, THP-1 cells carrying the TYK2-P1104A mutation were generated, and ICAM1 and cytokine expression were analyzed following LPS stimulation. The effect of the TYK2 inhibitor Deucravacitinib was tested in an imiquimod (IMQ)-induced psoriasis mouse model.

Results

SMR identified ICAM1 as a causal protein for psoriasis, regulated by the TYK2 SNP rs34536443. In TYK2-P1104A mutant THP-1 cells, LPS-induced ICAM1 expression was significantly reduced, with ICAM5 unaffected. The mutation also suppressed IL-1β, TNF-α, IL-6, and IL-18 expression, suggesting anti-inflammatory effects. Single-cell RNA-seq revealed enrichment of TYK2, ICAM1, and ICAM5 in dendritic cells and monocytes. In vivo, Deucravacitinib significantly downregulated ICAM1 in the IMQ-induced psoriasis model, with minimal effect on ICAM5.

Conclusion

This study identifies ICAM1 as a key mediator in psoriasis via SMR analysis and implicates the TYK2 SNP rs34536443 in its regulation. The TYK2-P1104A variant attenuates ICAM1 and cytokine expression, and Deucravacitinib downregulates ICAM1 in vivo. These findings provide mechanistic insights into the TYK2-ICAM1 axis and support the therapeutic potential of TYK2 inhibitors for psoriasis.

Weiterlesen

]]>187Sat, 23 Aug 2025 07:41:28 +0000Hydroxytyrosol ameliorates imiquimod-induced psoriasis-like dermatitis by modulating ERK and NF-κB signaling pathways in mice.https://www.psoriasis-news.de/articles.html/1_articles/hydroxytyrosol-ameliorates-imiquimod-induced-psoriasis-like-dermatitis-by-modulating-erk-and-nf-%CE%BAb-signaling-pathways-in-mice-r186/Weiterlesen

]]>186Sat, 23 Aug 2025 07:41:28 +0000Unraveling the Mystery: A Case Report of Erythrodermic Psoriasis as an Adverse Reaction to Wellbutrinhttps://www.psoriasis-news.de/articles.html/1_articles/unraveling-the-mystery-a-case-report-of-erythrodermic-psoriasis-as-an-adverse-reaction-to-wellbutrin-r185/No abstract supplied.

Weiterlesen

]]>185Sat, 23 Aug 2025 07:41:28 +0000A Large-Scale, Retrospective Analysis of Bath-Psoralen Plus Ultraviolet A Therapy for Psoriasis: A Single-Center Study.https://www.psoriasis-news.de/articles.html/1_articles/a-large-scale-retrospective-analysis-of-bath-psoralen-plus-ultraviolet-a-therapy-for-psoriasis-a-single-center-study-r184/Background/purposeWhile biologics and small-molecule inhibitors are first-line systemic treatments for psoriasis, phototherapy remains an alternative for patients unable to access these treatments because of medical or financial constraints. Narrow-band ultraviolet B (NB-UVB) is effective for localized psoriasis but less so for extensive disease. To address this limitation, bathwater delivery of psoralen plus ultraviolet A (bath-PUVA) was introduced in 2004. This study evaluates the efficacy, safety, and patient characteristics associated with bath-PUVA therapy in a large cohort.

Methods

This retrospective analysis included 229 patients (180 males, 49 females) treated with bath-PUVA from 2004 to September 2021. Baseline characteristics and treatment outcomes were assessed using the psoriasis area and severity index (PASI). Statistical analyses examined relationships between treatment outcomes and factors, including baseline PASI, body mass index (BMI), and smoking status.

Results

The mean baseline PASI score was 24.9. Bath-PUVA achieved PASI 75 in 80.4% of patients, PASI 90 in 44.1%, and PASI 100 in 2.6%, with efficacy comparable to biologics. Patients achieving PASI 90 had significantly higher baseline PASI scores (p = 0.005), while the number of irradiations required did not differ (p = 0.692). Higher baseline PASI scores correlated with elevated BMI (p = 0.002), but BMI did not influence improvement rates (p = 0.094). Smokers had significantly higher baseline PASI scores (p = 0.004) compared with non-smokers, yet smoking status did not affect improvement rates (p = 0.862).

Conclusion

Bath-PUVA demonstrates efficacy comparable with biologics for psoriasis, regardless of BMI or smoking status. This analysis supports its use as an effective and accessible treatment option for patients with extensive disease.

Weiterlesen

]]>184Sat, 23 Aug 2025 07:41:28 +0000Arthritis Mutilans: A Devastating Manifestation of Psoriatic Disease Without Dactylitis in a 61-Year-Old Patienthttps://www.psoriasis-news.de/articles.html/1_articles/arthritis-mutilans-a-devastating-manifestation-of-psoriatic-disease-without-dactylitis-in-a-61-year-old-patient-r183/No abstract supplied.

Weiterlesen

]]>183Sat, 23 Aug 2025 07:41:28 +0000